MWNA
DBTX

Marshall Wace North America’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Marshall Wace North America’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,522
Closed -$131K – 1884
2021
Q1 		$131K Buy
+11,522
New +$181K ﹤0.01% 1437

Other funds holding DBTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's DBTX Position: Q2 2021 in Review

Marshall Wace North America sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q2 2021, closing a stake of 11,522 shares — an estimated $131K sold.

Marshall Wace North America first reported a position in DBTX in Q1 2021 and held it in 1 quarter. The position peaked at $131K in Q1 2021. 46 funds tracked by Wall St. Rank hold DBTX as of Q2 2021.

  • Marshall Wace North America reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 11,522 Decibel Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $131K.
  • Marshall Wace North America first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Decibel Therapeutics, Inc. Common Stock position peaked at $131K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.